down arrow

Wuhan YZY Biopharma Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000063C4
HKD
3.20
0.00 (0.00%)

Sep 25

HKG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Wuhan YZY Biopharma Co., Ltd.

Why is Wuhan YZY Biopharma Co., Ltd. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 192.73% and Operating profit at 9.55% over the last 5 years
  • The company has a negative book value of Rs 59.06 crore
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -49.21%, its profits have risen by 13.5%
3
Below par performance in long term as well as near term
  • Along with generating -49.21% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Wuhan YZY Biopharma Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Wuhan YZY Biopharma Co., Ltd.
-49.21%
-0.98
58.19%
Hang Seng Hong Kong
-6.63%
-0.36
18.67%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
192.73%
EBIT Growth (5y)
9.55%
EBIT to Interest (avg)
-63.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.86
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-7.12
EV to EBIT
-4.63
EV to EBITDA
-4.87
EV to Capital Employed
-15.99
EV to Sales
6.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -7,073% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -106.99 %

OPERATING PROFIT(Q)

Highest at HKD -4.29 MM

PRE-TAX PROFIT(Q)

Highest at HKD -7.14 MM

NET PROFIT(Q)

Highest at HKD -7.14 MM

EPS(Q)

Highest at HKD -0.04

-1What is not working for the Company
CASH AND EQV(HY)

Lowest at HKD 87.83 MM

Here's what is working for Wuhan YZY Biopharma Co., Ltd.

Operating Profit
Highest at HKD -4.29 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Pre-Tax Profit
Highest at HKD -7.14 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit
At HKD -7.14 MM has Grown at 88.71%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit
Highest at HKD -7.14 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

Net Profit
At HKD -7.14 MM has Grown at 88.71%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS
Highest at HKD -0.04
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Debt-Equity Ratio
Lowest at -106.99 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -7,073% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Wuhan YZY Biopharma Co., Ltd.

Cash and Eqv
Lowest at HKD 87.83 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Footer loading